相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
Y. Kawaguchi et al.
BRITISH JOURNAL OF CANCER (2007)
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 study group
Jaffer A. Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 study group
Jaffer A. Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
Val Gebski et al.
LANCET ONCOLOGY (2007)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2007)
Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma
Yoshihiko Kawaguchi et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas
F. A. Puehringer-Oppermann et al.
DISEASES OF THE ESOPHAGUS (2007)
Novel targeted therapies for advanced esophageal cancer
C.-C. Lin et al.
DISEASES OF THE ESOPHAGUS (2007)
Activation of growth factor receptors in esophageal cancer - Implications for therapy
Simon Ekman et al.
ONCOLOGIST (2007)
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma
S. Chris Malaisrie et al.
CANCER (2006)
Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer
AP Sutter et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates
M Lindblad et al.
ANNALS OF SURGERY (2006)
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
ML Janmaat et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450
MZ Guo et al.
CANCER BIOLOGY & THERAPY (2006)
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
JA Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Adenocarcinoma of the esophagus and cardia: A review of the disease and its treatment
SR DeMeester
ANNALS OF SURGICAL ONCOLOGY (2006)
Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma
L Moureau-Zabotto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
BH Burmeister et al.
LANCET ONCOLOGY (2005)
Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - Systematic review
M Westerterp et al.
RADIOLOGY (2005)
ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma
F Teralshi et al.
FEBS LETTERS (2005)
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus
AM Mauer et al.
ANNALS OF ONCOLOGY (2005)
Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma
K Mimura et al.
CLINICAL CANCER RESEARCH (2005)
Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: Report of 549 cases
ZF Xiao et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Treatment of Wilms tumor: An international perspective
J de Kraker et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
K Mimura et al.
BRITISH JOURNAL OF CANCER (2005)
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
M Stahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy
Z Zhang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction
BHA von Rahden et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma
P Sunpaweravong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer
M Stahl et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein
S Sato et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment
HA Wieder et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy
S Nakagawa et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2004)
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery
J Jin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Endoscopic palliative treatment for esophageal and gastric cancer - Techniques, complications, and survival in a population-based cohort of 948 patients
AM Thompson et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2004)
Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy
MYV Homs et al.
EUROPEAN JOURNAL OF CANCER (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?
O Vrieze et al.
RADIOTHERAPY AND ONCOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma
JL Lee et al.
ANNALS OF ONCOLOGY (2004)
ERBB2 amplifications in esophageal adenocarcinoma
PS Dahlberg et al.
ANNALS OF THORACIC SURGERY (2004)
En bloc vs transhiatal esophagectorny for stage T3 N1 adenocarcinorna of the distal esophagus
J Johansson et al.
ARCHIVES OF SURGERY (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial
MYV Homs et al.
LANCET (2004)
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
Richard A. Malthaner et al.
BMC MEDICINE (2004)
Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus
AGEM de Boer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Two-step three-field lymph node dissection is beneficial for thoracic esophageal carcinoma
T Noguchi et al.
DISEASES OF THE ESOPHAGUS (2004)
Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: A phase I study
H Safran et al.
CANCER INVESTIGATION (2004)
Medical progress - Esophageal cancer
PC Enzinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma
M Akamatsu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer
SG Swisher et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus
A May et al.
GASTROINTESTINAL ENDOSCOPY (2003)
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy:: Results of a prospective trial
RJ Downey et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus
JBF Hulscher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
HPV infections and oesophageal cancer
KJ Syrjänen
JOURNAL OF CLINICAL PATHOLOGY (2002)
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol
A Abitbol et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995
AP Vizcaino et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
High-grade esophageal dysplasia: Long-term survival and quality of life after esophagectomy
JR Headrick et al.
ANNALS OF THORACIC SURGERY (2002)
Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma - An International Atomic Energy Agency Study
RK Sur et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
T Conroy et al.
ANNALS OF ONCOLOGY (2002)
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PV1 5-FU) with epirubicin, cisplatin, and PV15-FU in advanced esophagogastric cancer
P Ross et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
MB Polee et al.
BRITISH JOURNAL OF CANCER (2002)
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer
P Flamen et al.
ANNALS OF ONCOLOGY (2002)
Curative resection for esophageal adenocarcinoma - Analysis of 100 en bloc esophagectomies
JA Hagen et al.
ANNALS OF SURGERY (2001)
HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma
TP Brien et al.
HUMAN PATHOLOGY (2000)
分享论文
